Crinetics Pharmaceuticals, Inc. (CRNX) Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect

Crinetics Pharmaceuticals, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect

Crinetics Pharmaceuticals, Inc. (CRNX) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$46.16 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.

Financial Statements › Cash Flow › Change in Cash

us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-03

• Crinetics Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was $12.81M.
• Crinetics Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$169.98M.
• Crinetics Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was -$163.40M, a 177.94% decline from fiscal 2024.
• Crinetics Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was $209.65M, a 843.34% increase from fiscal 2023.
• Crinetics Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was $22.22M.